Jonathan M Blevitt Selected Research

1- (4- (6- amino- 5- (methoxyiminomethyl)pyrimidin- 4- yloxy)- 2- chlorophenyl)- 3- ethylurea

1/2009

A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jonathan M Blevitt Research Topics

Disease

2	Neoplasms (Cancer) 02/2016 - 01/2009
1	Cardiovascular Diseases (Cardiovascular Disease) 02/2016
1	Endotoxemia 08/2015
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 02/2013
1	Asthma (Bronchial Asthma) 02/2013
1	Autoimmune Diseases (Autoimmune Disease) 01/2010
1	Inflammation (Inflammations) 01/2010
1	Neoplasm Metastasis (Metastasis) 01/2009
1	Corneal Neovascularization 01/2009
1	Melanoma (Melanoma, Malignant) 03/2008

Drug/Important Bio-Agent (IBA)

1	LeukotrienesIBA 02/2016
1	Arachidonic Acid (Vitamin F)IBA 02/2016
1	LipidsIBA 02/2016
1	LipopolysaccharidesIBA 08/2015
1	benzofuranIBA 02/2013
1	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2010
1	Phosphotransferases (Kinase)IBA 01/2010
1	1- (4- (6- amino- 5- (methoxyiminomethyl)pyrimidin- 4- yloxy)- 2- chlorophenyl)- 3- ethylureaIBA 01/2009
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2009
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2009
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2009
1	Mitogen-Activated Protein Kinase 3IBA 03/2008
1	Biomarkers (Surrogate Marker)IBA 03/2008
1	Interleukin-8 (Interleukin 8)IBA 03/2008
1	AgarIBA 03/2008